Medical - Devices
Compare Stocks
5 / 10Stock Comparison
LIVN vs GKOS vs NVCR vs TNDM vs MDT
Revenue, margins, valuation, and 5-year total return — side by side.
Medical - Devices
Medical - Instruments & Supplies
Medical - Devices
Medical - Devices
LIVN vs GKOS vs NVCR vs TNDM vs MDT — Key Financials
Market cap, revenue, margins, and valuation side-by-side.
| Company Snapshot | |||||
|---|---|---|---|---|---|
| Industry | Medical - Devices | Medical - Devices | Medical - Instruments & Supplies | Medical - Devices | Medical - Devices |
| Market Cap | $3.88B | $7.85B | $1.92B | $1.27B | $99.94B |
| Revenue (TTM) | $1.43B | $551M | $674M | $1.03B | $35.48B |
| Net Income (TTM) | $107M | $-189M | $-173M | $-95M | $4.61B |
| Gross Margin | 67.5% | 78.1% | 75.2% | 54.9% | 61.9% |
| Operating Margin | 13.4% | -15.6% | -27.2% | -7.9% | 17.9% |
| Forward P/E | 16.8x | — | — | — | 14.1x |
| Total Debt | $473M | $140M | $290M | $444M | $28.52B |
| Cash & Equiv. | $636M | $91M | $103M | $91M | $2.22B |
LIVN vs GKOS vs NVCR vs TNDM vs MDT — Long-Term Stock Performance
Price return indexed to 100 at period start. Dividends excluded.
| Stock | May 20 | May 26 | Return |
|---|---|---|---|
| LivaNova PLC (LIVN) | 100 | 132.6 | +32.6% |
| Glaukos Corporation (GKOS) | 100 | 344.2 | +244.2% |
| NovoCure Limited (NVCR) | 100 | 25.0 | -75.0% |
| Tandem Diabetes Car… (TNDM) | 100 | 22.2 | -77.8% |
| Medtronic plc (MDT) | 100 | 79.1 | -20.9% |
Price return only. Dividends and distributions are not included.
Quick Verdict: LIVN vs GKOS vs NVCR vs TNDM vs MDT
Each card shows where this stock fits in a portfolio — not just who wins on paper.
LIVN is the #2 pick in this set and the best alternative if momentum is your priority.
- +63.0% vs TNDM's -17.0%
GKOS ranks third and is worth considering specifically for growth exposure and long-term compounding.
- Rev growth 32.3%, EPS growth -18.4%, 3Y rev CAGR 21.5%
- 457.1% 10Y total return vs LIVN's 46.2%
- Lower volatility, beta 1.20, Low D/E 21.3%, current ratio 4.69x
- Beta 1.20, current ratio 4.69x
NVCR lags the leaders in this set but could rank higher in a more targeted comparison.
Among these 5 stocks, TNDM doesn't own a clear edge in any measured category.
MDT carries the broadest edge in this set and is the clearest fit for income & stability.
- Dividend streak 36 yrs, beta 0.47, yield 3.6%
- Better valuation composite
- 13.0% margin vs GKOS's -34.3%
- Beta 0.47 vs NVCR's 2.20, lower leverage
See the full category breakdown
| Category | Winner | Why |
|---|---|---|
| Growth | 32.3% revenue growth vs MDT's 3.6% | |
| Value | Better valuation composite | |
| Quality / Margins | 13.0% margin vs GKOS's -34.3% | |
| Stability / Safety | Beta 0.47 vs NVCR's 2.20, lower leverage | |
| Dividends | 3.6% yield; 36-year raise streak; the other 4 pay no meaningful dividend | |
| Momentum (1Y) | +63.0% vs TNDM's -17.0% | |
| Efficiency (ROA) | 175.8% ROA vs GKOS's -20.1%, ROIC 6.0% vs -9.2% |
LIVN vs GKOS vs NVCR vs TNDM vs MDT — Revenue Breakdown by Segment
How each company's revenue is distributed across its business units
Segment breakdown not available.
LIVN vs GKOS vs NVCR vs TNDM vs MDT — Financial Metrics
Side-by-side numbers across 5 stocks — who leads on profitability, valuation, growth, and risk.
Who Leads Where
MDT leads in 3 of 6 categories
GKOS leads 1 • LIVN leads 0 • NVCR leads 0 • TNDM leads 0 • 1 tied
Explore the data ↓Income & Cash Flow (Last 12 Months)
MDT leads this category, winning 3 of 6 comparable metrics.
Income & Cash Flow (Last 12 Months)
MDT is the larger business by revenue, generating $35.5B annually — 64.4x GKOS's $551M. MDT is the more profitable business, keeping 13.0% of every revenue dollar as net income compared to GKOS's -34.3%. On growth, GKOS holds the edge at +41.2% YoY revenue growth, suggesting stronger near-term business momentum.
| Metric | |||||
|---|---|---|---|---|---|
| RevenueTrailing 12 months | $1.4B | $551M | $674M | $1.0B | $35.5B |
| EBITDAEarnings before interest/tax | $220M | -$40M | -$165M | -$68M | $9.4B |
| Net IncomeAfter-tax profit | $107M | -$189M | -$173M | -$95M | $4.6B |
| Free Cash FlowCash after capex | $161M | -$18M | -$48M | -$4M | $5.4B |
| Gross MarginGross profit ÷ Revenue | +67.5% | +78.1% | +75.2% | +54.9% | +61.9% |
| Operating MarginEBIT ÷ Revenue | +13.4% | -15.6% | -27.2% | -7.9% | +17.9% |
| Net MarginNet income ÷ Revenue | +7.5% | -34.3% | -25.7% | -9.2% | +13.0% |
| FCF MarginFCF ÷ Revenue | +11.2% | -3.4% | -7.1% | -0.4% | +15.2% |
| Rev. Growth (YoY)Latest quarter vs prior year | +14.3% | +41.2% | +12.3% | +5.5% | +8.8% |
| EPS Growth (YoY)Latest quarter vs prior year | +106.7% | -6.3% | -100.0% | +84.8% | -11.9% |
Valuation Metrics
MDT leads this category, winning 4 of 6 comparable metrics.
Valuation Metrics
On an enterprise value basis, MDT's 14.3x EV/EBITDA is more attractive than LIVN's 15.4x.
| Metric | |||||
|---|---|---|---|---|---|
| Market CapShares × price | $3.9B | $7.9B | $1.9B | $1.3B | $99.9B |
| Enterprise ValueMkt cap + debt − cash | $3.7B | $7.9B | $2.1B | $1.6B | $126.2B |
| Trailing P/EPrice ÷ TTM EPS | -15.94x | -40.90x | -13.80x | -6.08x | 21.60x |
| Forward P/EPrice ÷ next-FY EPS est. | 16.84x | — | — | — | 14.13x |
| PEG RatioP/E ÷ EPS growth rate | — | — | — | — | 36.00x |
| EV / EBITDAEnterprise value multiple | 15.40x | — | — | — | 14.32x |
| Price / SalesMarket cap ÷ Revenue | 2.79x | 15.47x | 2.92x | 1.25x | 2.98x |
| Price / BookPrice ÷ Book value/share | 3.22x | 11.69x | 5.51x | 8.01x | 2.08x |
| Price / FCFMarket cap ÷ FCF | 22.40x | — | — | — | 19.28x |
Profitability & Efficiency
MDT leads this category, winning 4 of 9 comparable metrics.
Profitability & Efficiency
MDT delivers a 9.4% return on equity — every $100 of shareholder capital generates $9 in annual profit, vs $-68 for TNDM. GKOS carries lower financial leverage with a 0.21x debt-to-equity ratio, signaling a more conservative balance sheet compared to TNDM's 2.86x. On the Piotroski fundamental quality scale (0–9), MDT scores 6/9 vs TNDM's 3/9, reflecting solid financial health.
| Metric | |||||
|---|---|---|---|---|---|
| ROE (TTM)Return on equity | +9.1% | -26.5% | -50.8% | -68.3% | +9.4% |
| ROA (TTM)Return on assets | +4.2% | -20.1% | -16.5% | -10.0% | +175.8% |
| ROICReturn on invested capital | +11.5% | -9.2% | -16.4% | -10.0% | +6.0% |
| ROCEReturn on capital employed | +10.2% | -10.3% | -28.9% | -11.5% | +7.5% |
| Piotroski ScoreFundamental quality 0–9 | 5 | 3 | 5 | 3 | 6 |
| Debt / EquityFinancial leverage | 0.39x | 0.21x | 0.85x | 2.86x | 0.59x |
| Net DebtTotal debt minus cash | -$162M | $49M | $187M | $354M | $26.3B |
| Cash & Equiv.Liquid assets | $636M | $91M | $103M | $91M | $2.2B |
| Total DebtShort + long-term debt | $473M | $140M | $290M | $444M | $28.5B |
| Interest CoverageEBIT ÷ Interest expense | 3.98x | -18.69x | -96.80x | -15.99x | 9.08x |
Total Returns (Dividends Reinvested)
GKOS leads this category, winning 4 of 6 comparable metrics.
Total Returns (Dividends Reinvested)
A $10,000 investment in GKOS five years ago would be worth $16,155 today (with dividends reinvested), compared to $875 for NVCR. Over the past 12 months, LIVN leads with a +63.0% total return vs TNDM's -17.0%. The 3-year compound annual growth rate (CAGR) favors GKOS at 31.7% vs NVCR's -37.6% — a key indicator of consistent wealth creation.
| Metric | |||||
|---|---|---|---|---|---|
| YTD ReturnYear-to-date | +17.0% | +21.2% | +28.3% | -14.3% | -18.1% |
| 1-Year ReturnPast 12 months | +63.0% | +52.0% | +1.1% | -17.0% | -2.8% |
| 3-Year ReturnCumulative with dividends | +50.5% | +128.7% | -75.7% | -44.8% | -4.2% |
| 5-Year ReturnCumulative with dividends | -14.5% | +61.5% | -91.3% | -78.0% | -27.7% |
| 10-Year ReturnCumulative with dividends | +46.2% | +457.1% | +30.3% | -75.4% | +26.5% |
| CAGR (3Y)Annualised 3-year return | +14.6% | +31.7% | -37.6% | -18.0% | -1.4% |
Risk & Volatility
Evenly matched — LIVN and MDT each lead in 1 of 2 comparable metrics.
Risk & Volatility
MDT is the less volatile stock with a 0.47 beta — it tends to amplify market swings less than NVCR's 2.20 beta. A beta below 1.0 means the stock typically moves less than the S&P 500. LIVN currently trades 98.6% from its 52-week high vs TNDM's 62.3% drawdown — a narrower gap to the peak suggests stronger recent price momentum.
| Metric | |||||
|---|---|---|---|---|---|
| Beta (5Y)Sensitivity to S&P 500 | 1.29x | 1.20x | 2.20x | 1.45x | 0.47x |
| 52-Week HighHighest price in past year | $71.92 | $146.75 | $20.06 | $29.65 | $106.33 |
| 52-Week LowLowest price in past year | $39.36 | $73.16 | $9.82 | $9.98 | $77.16 |
| % of 52W HighCurrent price vs 52-week peak | +98.6% | +91.4% | +83.9% | +62.3% | +73.3% |
| RSI (14)Momentum oscillator 0–100 | 57.6 | 63.0 | 69.8 | 39.1 | 27.3 |
| Avg Volume (50D)Average daily shares traded | 808K | 678K | 1.5M | 1.8M | 7.8M |
Analyst Outlook
Insufficient data to determine a leader in this category.
Analyst Outlook
Analyst consensus: LIVN as "Buy", GKOS as "Buy", NVCR as "Buy", TNDM as "Buy", MDT as "Buy". Consensus price targets imply 99.0% upside for NVCR (target: $34) vs 7.0% for LIVN (target: $76). MDT is the only dividend payer here at 3.57% yield — a key consideration for income-focused portfolios.
| Metric | |||||
|---|---|---|---|---|---|
| Analyst RatingConsensus buy/hold/sell | Buy | Buy | Buy | Buy | Buy |
| Price TargetConsensus 12-month target | $75.88 | $146.67 | $33.50 | $31.62 | $109.50 |
| # AnalystsCovering analysts | 14 | 24 | 15 | 39 | 49 |
| Dividend YieldAnnual dividend ÷ price | — | — | — | — | +3.6% |
| Dividend StreakConsecutive years of raises | — | — | — | — | 36 |
| Dividend / ShareAnnual DPS | — | — | — | — | $2.78 |
| Buyback YieldShare repurchases ÷ mkt cap | +0.1% | 0.0% | 0.0% | 0.0% | +3.2% |
MDT leads in 3 of 6 categories (Income & Cash Flow, Valuation Metrics). GKOS leads in 1 (Total Returns). 1 tied.
LIVN vs GKOS vs NVCR vs TNDM vs MDT: Key Questions Answered
10 questions · data-driven answers · updated daily
01Is LIVN or GKOS or NVCR or TNDM or MDT a better buy right now?
For growth investors, Glaukos Corporation (GKOS) is the stronger pick with 32.
3% revenue growth year-over-year, versus 3. 6% for Medtronic plc (MDT). Medtronic plc (MDT) offers the better valuation at 21. 6x trailing P/E (14. 1x forward), making it the more compelling value choice. Analysts rate LivaNova PLC (LIVN) a "Buy" — based on 14 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.
02Which has the better valuation — LIVN or GKOS or NVCR or TNDM or MDT?
On forward P/E, Medtronic plc is actually cheaper at 14.
1x.
03Which is the better long-term investment — LIVN or GKOS or NVCR or TNDM or MDT?
Over the past 5 years, Glaukos Corporation (GKOS) delivered a total return of +61.
5%, compared to -91. 3% for NovoCure Limited (NVCR). Over 10 years, the gap is even starker: GKOS returned +457. 1% versus TNDM's -75. 4%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.
04Which is safer — LIVN or GKOS or NVCR or TNDM or MDT?
By beta (market sensitivity over 5 years), Medtronic plc (MDT) is the lower-risk stock at 0.
47β versus NovoCure Limited's 2. 20β — meaning NVCR is approximately 373% more volatile than MDT relative to the S&P 500. On balance sheet safety, Glaukos Corporation (GKOS) carries a lower debt/equity ratio of 21% versus 3% for Tandem Diabetes Care, Inc. — giving it more financial flexibility in a downturn.
05Which is growing faster — LIVN or GKOS or NVCR or TNDM or MDT?
By revenue growth (latest reported year), Glaukos Corporation (GKOS) is pulling ahead at 32.
3% versus 3. 6% for Medtronic plc (MDT). On earnings-per-share growth, the picture is similar: Medtronic plc grew EPS 30. 8% year-over-year, compared to -483. 6% for LivaNova PLC. Over a 3-year CAGR, GKOS leads at 21. 5% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.
06Which has better profit margins — LIVN or GKOS or NVCR or TNDM or MDT?
Medtronic plc (MDT) is the more profitable company, earning 13.
9% net margin versus -37. 0% for Glaukos Corporation — meaning it keeps 13. 9% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: MDT leads at 17. 8% versus -23. 5% for NVCR. At the gross margin level — before operating expenses — GKOS leads at 77. 5%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.
07Is LIVN or GKOS or NVCR or TNDM or MDT more undervalued right now?
On forward earnings alone, Medtronic plc (MDT) trades at 14.
1x forward P/E versus 16. 8x for LivaNova PLC — 2. 7x cheaper on a one-year earnings basis. Analyst consensus price targets imply the most upside for NVCR: 99. 0% to $33. 50.
08Which pays a better dividend — LIVN or GKOS or NVCR or TNDM or MDT?
In this comparison, MDT (3.
6% yield) pays a dividend. LIVN, GKOS, NVCR, TNDM do not pay a meaningful dividend and should not be held primarily for income.
09Is LIVN or GKOS or NVCR or TNDM or MDT better for a retirement portfolio?
For long-horizon retirement investors, Medtronic plc (MDT) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 0.
47), 3. 6% yield). NovoCure Limited (NVCR) carries a higher beta of 2. 20 — meaning larger drawdowns in market downturns, which matters significantly when you cannot wait years for a recovery. Both have compounded well over 10 years (MDT: +26. 5%, NVCR: +30. 3%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.
10What are the main differences between LIVN and GKOS and NVCR and TNDM and MDT?
Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both.
In terms of investment character: LIVN is a small-cap quality compounder stock; GKOS is a small-cap high-growth stock; NVCR is a small-cap quality compounder stock; TNDM is a small-cap quality compounder stock; MDT is a mid-cap income-oriented stock. MDT pays a dividend while LIVN, GKOS, NVCR, TNDM do not, making them suitable for different income and tax situations. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.
Find Stocks Like These
Explore pre-built screens for each stock's profile, or build a custom screen to find stocks that outperform all of them.
You Might Also Compare
Based on how these companies actually compete and overlap — not just which sector they're filed under.